Wells Fargo & Company Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Posted by George Bondi on Nov 5th, 2026

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) had its price target lifted by investment analysts at Wells Fargo & Company from $31.00 to $34.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would indicate a potential upside of 15.23% from the company’s previous close.

VRDN has been the topic of a number of other research reports. Wall Street Zen cut Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Weiss Ratings upgraded Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 14th. Wedbush upped their price objective on shares of Viridian Therapeutics from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Thursday. Needham & Company LLC increased their target price on shares of Viridian Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Truist Financial upped their price target on shares of Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.27.

Read Our Latest Research Report on VRDN

Viridian Therapeutics Stock Performance

Shares of VRDN stock traded up $0.45 during trading hours on Thursday, hitting $29.50. 292,380 shares of the company were exchanged, compared to its average volume of 2,144,648. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $3.34 billion, a price-to-earnings ratio of -8.76 and a beta of 1.07. The firm has a fifty day simple moving average of $21.80 and a 200 day simple moving average of $21.85. Viridian Therapeutics has a 52-week low of $13.18 and a 52-week high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.21. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%. The business had revenue of $25.75 million during the quarter, compared to analyst estimates of $4.72 million. Research analysts predict that Viridian Therapeutics will post -4.07 earnings per share for the current fiscal year.

Insider Transactions at Viridian Therapeutics

In related news, insider Jennifer Tousignant sold 14,212 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Parkman Healthcare Partners LLC purchased a new stake in shares of Viridian Therapeutics in the 2nd quarter valued at about $25,306,000. Rice Hall James & Associates LLC bought a new position in shares of Viridian Therapeutics during the second quarter valued at about $21,601,000. Elmind Capital LP bought a new stake in Viridian Therapeutics in the second quarter valued at approximately $18,093,182. Bank of America Corp DE bought a new stake in Viridian Therapeutics in the second quarter valued at approximately $17,348,000. Finally, Deutsche Bank AG purchased a new stake in shares of Viridian Therapeutics during the second quarter valued at approximately $8,870,000.

More Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

Positive Sentiment: Analysts raised their targets and maintained bullish ratings: Wedbush increased its target to $42 and kept an “outperform” rating; HC Wainwright raised its target to $40 and kept a “buy” rating; and Needham lifted its target to $38 with a “buy” rating. Read More., Read More., Read More.
Positive Sentiment: Viridian reported a Q3 loss of $0.81 per share, narrower than analysts’ roughly $1.01–$1.02 estimate, while revenue of $25.75 million exceeded the $4.72 million estimate. The earnings beat may have supported investor sentiment, although the loss was larger than a year earlier. Read More.
Positive Sentiment: The company signaled it is targeting a Q1 2027 biologics license application for elegrobart and expects Lumvoa’s launch to pursue broad coverage over the next six to nine months. Progress toward regulatory submission and commercial access could strengthen the pipeline and launch outlook. Read More.
Negative Sentiment: A separate analysis argued that VRDN may be overvalued even with its new launch, raising a potential concern about how much expected commercial progress is already reflected in the shares. Read More.

Viridian Therapeutics Company Profile

(Get Free Report)

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.